Subjective Well Being of Patients Receiving Atypical Antipsychotics as Monotherapy or Cotherapy With Mood Stabilizers
NCT ID: NCT00691353
Last Updated: 2008-12-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
540 participants
OBSERVATIONAL
2008-04-30
2008-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
* Target Group: Patients that suffer from Bipolar Disorder Type 1.
* YMRS - HAMILTON and GAF scales are going to be used to assess the clinical outcome. The findings are going to be based on the different scores reported by Specialists (before the patients started to use as a therapy atypical antipsychotics / at the time that the visit actually takes place for the cause of the study.) We predefine the time period that the patient should be using atypical antipsychotics at minimum (2 months).
* The first 9 consecutive patients that visit the Specialist and meet the entry criteria and signs the ICF will be recruited in the study.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
CROSS_SECTIONAL
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients that have started therapy with atypical antipsychotics as monotherapy or cotherapy with mood stabilizers the last three months, but have completed 2 full months of therapy.
* Patients with anxiety disorder can be recruited in the study unless it is dominant.
Exclusion Criteria
* Patients who were treated with depot antipsychotic in the last quarter before their enrollment in the study.
* Patients who are addicts of toxic substances.
* Patients who suffer from other serious diseases.
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AstraZeneca
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
AstraZeneca, SA Greece
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Charalambos Touloumis, MD
Role: PRINCIPAL_INVESTIGATOR
Athens Psychiatric Hospital Greece
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research Site
Agrinio, , Greece
Research Site
Alexandroupoli, , Greece
Research Site
Athens, , Greece
Research Site
Crete, , Greece
Research Site
Elefsina, , Greece
Research Site
Ioannina, , Greece
Research Site
Karditsa, , Greece
Research Site
Katerini, , Greece
Research Site
Kos, , Greece
Research Site
Kozani, , Greece
Research Site
Lamia, , Greece
Research Site
Larissa, , Greece
Research Site
Nafplion, , Greece
Research Site
Pátrai, , Greece
Research Site
Piraeus, , Greece
Research Site
Rhodes, , Greece
Research Site
Serres, , Greece
Research Site
Thebes, , Greece
Research Site
Thessalonii, , Greece
Research Site
Thessaloniki, , Greece
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NIS-NGR-DUM-2008/1
Identifier Type: -
Identifier Source: org_study_id